Lagging Immune Response to Serotype b (Hib) Conjugate Vaccine after the Primary Vaccination with Hib of Infants in The Netherlands.
dc.contributor.author | Schouls, Leo | |
dc.contributor.author | Schot, Corrie | |
dc.contributor.author | de Voer, Richarda M | |
dc.contributor.author | van der Klis, Fiona | |
dc.contributor.author | Knol, Mirjam | |
dc.contributor.author | Tcherniaeva, Irina | |
dc.contributor.author | Berbers, Guy | |
dc.date.accessioned | 2020-07-17T08:48:25Z | |
dc.date.available | 2020-07-17T08:48:25Z | |
dc.date.issued | 2020-06-30 | |
dc.identifier.issn | 2076-393X | |
dc.identifier.pmid | 32629935 | |
dc.identifier.doi | 10.3390/vaccines8030347 | |
dc.identifier.uri | http://hdl.handle.net/10029/623977 | |
dc.description.abstract | In 1993, a Haemophilus influenzae serotype b (Hib) conjugate vaccine was introduced in the Dutch national immunization program, resulting in a sharp decrease in invasive Hib disease. We used a population-based set of serum samples collected in the Netherlands in 2006-2007 (Pienter-II, 5696 sera) to assess the concentration of antibodies to the capsular polysaccharide of Hib, and compared the results with those obtained from a similar set collected in 1995-1996 (Pienter-I, 7837 sera). Post-primary vaccination serum samples from children aged 6-11 months from the Pienter-II study contained approximately 4-fold lower anti-Hib antibody concentrations than samples from children from the Pienter-I study. No such difference was found in post-booster samples from children older than 11 months of age. In Pienter-II, the proportion of children aged 6-11 months with anti-Hib antibody concentrations below the putative protective concentration of 0.15 µg/mL was 30%, which is significantly higher than in the Pienter-I study (12%). Fewer children in the Pienter-II group developed antibodies able to kill Hib in a serum bactericidal assay compared to the Pienter-I children. The cause of the lagged response in Pienter-II children remain uncertain, but lack of natural boosting, interference by the acellular pertussis vaccine, combining vaccines and acceleration of the schedule may have contributed. | en_US |
dc.language.iso | en | en_US |
dc.subject | Hib | en_US |
dc.subject | Netherlands | en_US |
dc.subject | reduced immunogenicity | en_US |
dc.subject | vaccination | en_US |
dc.title | Lagging Immune Response to Serotype b (Hib) Conjugate Vaccine after the Primary Vaccination with Hib of Infants in The Netherlands. | en_US |
dc.type | Article | en_US |
dc.identifier.journal | Vaccines 2020; 8(3):pii.e347 | en_US |
dc.source.journaltitle | Vaccines |